Personal CFO Solutions LLC Buys 113 Shares of Johnson & Johnson (NYSE:JNJ)

Personal CFO Solutions LLC boosted its stake in Johnson & Johnson (NYSE:JNJFree Report) by 0.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,779 shares of the company’s stock after purchasing an additional 113 shares during the period. Personal CFO Solutions LLC’s holdings in Johnson & Johnson were worth $2,317,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. WealthPlan Investment Management LLC boosted its holdings in Johnson & Johnson by 495.4% in the 3rd quarter. WealthPlan Investment Management LLC now owns 67,728 shares of the company’s stock worth $10,549,000 after buying an additional 56,352 shares during the period. Blackhawk Capital Partners LLC. boosted its holdings in Johnson & Johnson by 3.3% in the 3rd quarter. Blackhawk Capital Partners LLC. now owns 10,567 shares of the company’s stock worth $1,646,000 after buying an additional 340 shares during the period. Clearstead Advisors LLC boosted its holdings in Johnson & Johnson by 20.3% in the 3rd quarter. Clearstead Advisors LLC now owns 97,006 shares of the company’s stock worth $15,109,000 after buying an additional 16,357 shares during the period. Gryphon Financial Partners LLC boosted its holdings in Johnson & Johnson by 1.5% in the 3rd quarter. Gryphon Financial Partners LLC now owns 8,565 shares of the company’s stock worth $1,334,000 after buying an additional 128 shares during the period. Finally, LCM Capital Management Inc boosted its holdings in Johnson & Johnson by 4.8% in the 3rd quarter. LCM Capital Management Inc now owns 10,422 shares of the company’s stock worth $1,623,000 after buying an additional 475 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America decreased their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. The Goldman Sachs Group started coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday. Finally, HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Trading Up 0.5 %

NYSE:JNJ traded up $0.66 during mid-day trading on Friday, hitting $147.08. 5,111,626 shares of the stock traded hands, compared to its average volume of 7,280,428. The stock has a market capitalization of $353.97 billion, a price-to-earnings ratio of 9.17, a PEG ratio of 2.43 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The firm’s 50 day moving average is $149.27 and its two-hundred day moving average is $154.88. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the firm posted $2.68 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.